TY - JOUR T1 - Access to healthcare as an important moderating variable for understanding geography of immunity levels for COVID-19 - preliminary insights from Poland JF - medRxiv DO - 10.1101/2021.12.08.21267167 SP - 2021.12.08.21267167 AU - Andrzej Jarynowski AU - Vitaly Belik Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267167.abstract N2 - Background Underascertainment of COVID-19 burden and uncertainty in estimation of immunity levels is a known and common phenomenon in infectious diseases. We tested to what extent healthcare access (HCA) related supply/demand interfered with registered data on COVID-19 from Poland.Material and methods We have run a multiple linear regressions model with interactions to explain geographical variability in seroprevalence, hospitalization (on voivodeship –NUTS-2– level) and current (beginning of the 4th wave –15.09-21.11.2021) case notifications/crude mortality (on poviats –old NUTS-4– level) taking vaccination coverage and cumulative case notifications till so called 3rd wave as predictor variables and supply/demand (HCA) as moderating variables.Results HCA with interacting terms (mainly demand) explained to the great extent the variance of current incidence and most variance in case of current mortality. HCA (mainly supply) is significantly moderating cumulative case notifications till the 3rd wave explaining the variance across seroprevalence.Conclusions Seeking causal relations between vaccination or infection gained immunity level and current infection dynamics could be misleading without understanding socio-epidemiological context such as the moderating role of HCA (sensu lato). After quantification, HCA could be incorporated into epidemiological models for better prediction of real disease burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by DFG (German Research Foundation, project number 458528774).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data:seroprevalence, hospitalization, case notifications, crude mortality, vaccination coverage, supply/demand healthcare access indexes. Sources: Statistics Poland, Ministry of Health Poland, Crisis Management PolandI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced and processing scripts are available online at Github https://github.com/ajarynowski/Healtcare_Access_COVID/ ER -